A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC.
Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR, ALK, ROS1, RET).
Histologically confirmed stage III disease.
PD-L1 TPS ≥ 1% according to local testing.
No evidence of EGFR mutations or ALK or ROS1 or RET rearrangements by local testing.
Pulmonary function tests within 6 months of the planned resection.
Histology of large cell neuroendocrine carcinoma (LCNEC).
Any previous therapy for current lung cancer, including chemotherapy or radiation therapy.
Previous treatment with an antibody or drug against the immune checkpoint pathway, including but not limited to, therapeutic anti-cytotoxic T-lymphocyte antigen-4-associated antibodies (anti-CTLA-4), anti-PD-1 and anti-PD-L1.
Never smoking patients.